Public Policy Resources

Share

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources

FILTER BY:

Photo of female cancer patient

Patient Quality of Life

ACS CAN advocates for policies that improve the lives of cancer patients by making treatment of their pain and other symptoms and coordination of their care standard protocol throughout their treatment for cancer, starting at the point of diagnosis.
 

Featured Resources

 

In August-September 2019, the American Cancer Society Cancer Action Network (ACS CAN) — through its Survivor Views Project  — conducted a survey of cancer patients and survivors to determine whether they were asking for and getting appropriate palliative care treatment. 

This table lists key studies and review articles that examine the effect that the addition of palliative care has on overall patient costs. While results vary, the addition of palliative care typically either reduces overall costs or is cost neutral.

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Precision medicine in cancer involves targeted therapies which work by interfering with specific cellular processes involved in the growth, spread, and progression of cancer. Treatment with targeted therapy often requires diagnostic testing to identify specific cancer biomarkers. Testing patients for biomarkers is integral to precision medicine in cancer care.

Every five years the FDA drug user fees are reauthorized, offering an opportunity to influence priorities.  ACS CAN is recommending an increased focus on patient representation in regulatory decision making, guidance to drive increased use of decentralized trials, and a scientific focus on dispar

Advances in precision medicine have led to targeted cancer therapies that have improved patient outcomes and quality of life within populations of cancer patients with very specific biomarkers. Testing patients for cancer biomarkers is integral to identify those who may benefit from targeted therapy. Despite the importance of such testing, many cancer patients are not tested for biomarkers. This fact sheet highlights recent advancements in targeted cancer therapies and data from ACS CAN Survivor Views surveys of cancer patients and survivors assessing barriers to biomarker testing.  

Photo of ACS CAN Volunteers participating in health care reform Lobby Day event

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

ACS CAN encourages policymakers at all levels to continue exploring this issue. ACS CAN supports policies at the national, state and local levels that increase access to job-protected paid family & medical leave that can be used for cancer treatments, survivorship care, and caregiving as well as other illnesses. Read this factsheet to learn more.

ACS CAN submitted comments on September 16, 2020, to CMS regarding Georgia's 1332 waiver application.

Despite notable advances in cancer prevention, screening, and treatment, not all individuals benefit equally from this important progress. This fact sheet provides an overview of current health disparities in cancer care and a snapshot of ACS CAN federal advocacy activities to eliminate these disparities and achieve health equity.

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

This factsheet reviews recommended guidelines and insurance coverge for lung cancer screening.

American Cancer Society Cancer Action Network, American Academy of Pediatrics, American Heart Association, American Lung Association, Campaign for Tobacco-Free Kids, and Truth Initiative present the following principles FDA should use when implementing the premarket review process for tobacco products.

This factsheet provides a summary of the premarket review requirements and status of FDA's enforcement of the requirements.